CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Lovastatin 2%, 2% Cholesterol Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04359823
NCT04359823Phase 1Completed

Topical Treatment for Superficial Disseminated Actinic Porokeratosis: A Single-Blinded Comparison Between Lovastatin/Cholesterol and Lovastatin

Medical University of South Carolina·interventional·Posted Apr 24, 2020·Updated Dec 7, 2023

In Brief

A Phase 1 clinical trial evaluating Lovastatin 2%, 2% Cholesterol Cream and Lovastatin 2% Cream for Actinic Porokeratosis. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study will analyze the effects of topical lovastatin/cholesterol vs topical lovastatin alone in patients with disseminated superficial actinic porokeratosis. Patients will be divided into two groups, topical lovastatin/cholesterol and topical lovastatin alone. Patients will apply topical treatment twice daily to lesions over the course of 12 weeks. Follow up will occur in the virtual setting and photographs will be used to document progress.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedApr 24, 2020
Enrollment StartAug 24, 2020
Primary CompletionApr 23, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.2 years ago

Interventions

Lovastatin 2%, 2% Cholesterol Creamdrug

Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.

Lovastatin 2% Creamdrug

Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.